检索结果-南通市图书馆

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China： A Prospective, Multicenter, Noninterventional Study

引用

Chinese Medical Journal 2018年第15期131卷 1767-1775页

作者： Jian-Qiu WU Yong-Ping Song Li-Ping Su Ming-Zhi Zhang Wei Li Yu Hu Xiao-Hong Zhang Yu-Huan Gao Zuo-Xing Niu Ru Feng Wei Wang Jie-Wen Peng Xiao-Lin Li Xue-Nong Ouyang Chang-Ping Wu Wei-Jing Zhang Yun Zeng Zhen Xiao Ying-Min Liang Yong-Zhi Zhuang Ji-Shi Wang Zi-Min Sun Hai Bai Tong-Jian Cui Ji-Feng Feng Department of Oncology Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital Nanjing Jiangsu 210008 China Department of Hematology Henan Cancer Hospital Zhengzhou Henan 450000 China Department of Hematology Shanxi Cancer Hospital Taiyuan Shanxi 030013 China Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450000 China Department of Oncology Jilin University First Affiliated Hospital Changchun Jilin 130000 China Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430072 China Department of Hematology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China Department of Hematology Fourth Hospital of Hebei Medical University Shijiazhuang Hebei 050000 China Department of Oncology Affiliated Hospital of Shandong Academy of Medical Sciences Jinan Shandong 250000 China Department of Hematology Medical University Nanfang Hospital Guangzhou Guangdong 510000 China Department of Oncology Guangdong Foshan First Hospital Foshan Guangdong 528000 China Department of Oncology Guangdong Zhongshan People's Hospital Zhongshan Guangdong 528403 China Department of Hematology Xiangya Hospital Central South University Changsha Hunan 410008 China Department of Oncology Fuzhou General Hospital of Nanjing Military Command Fuzhou Fujian 350001 China Department of Oncology Changzhou First People's Hospital Changzhou Jiangsu 213000 China Department of Oncology 307 Hospital of Chinese People's Liberation Army Beijing 100070 China TDepartment of Hematology First Affiliated Hospital of Kunming Medical University Kunming Yunnan 650221 China Department of Hematology Affiliated Hospital of Neimenggu Medical College Hohhot Huhehaote Inner Mongolia 010050 China Department of Hematology The Fourth Military Medical University Affiliated Tangdu Hospital X

Background： Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma （DLBCL） or follicular lymphoma （FL） are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes ofrituximab plus chemotherapy （R-chemo） as first-line treatment in Chinese patients with DLBCL or FL. Hepatitis B virus （HBV） reactivation management was also investigated. Methods： A prospective, multicenter, single-arm, noninterventional study of previously untreated CD20-positive DLBCL or FL patients receiving first-line R-chemo treatment at 24 centers in China was conducted between January 17, 2011 and October 31, 2016. Enrolled patients underwent safety and effectiveness assessments after the last rituximab dose and were followed up for 3 years. Effectiveness endpoints included progression-free survival （PFS） and overall survival （OS）. Safety endpoints were adverse events （AEs）, serious AEs, drug-related AEs, and AEs of special interest. We also reported data on the incidence of HBV reactivation. Results： In total, 283 previously untreated CD20-positive DLBCL and 31 FL patients from 24 centers were enrolled. Three-year PFS was 59% （95% confidence interval [CI]： 50-67%） for DLBCL patients and 46% （95% CI： 20-69%） for FL patients. For DLBCL patients, multivariate analyses showed that PFS was not associated with international prognostic index, tumor maximum diameter, HBV infection status, or number ofrituximab treatment cycles, and OS was only associated with age 〉60 years （P 〈 0.05）. R-chemo was well tolerated. The incidence of HBV reactivation in hepatitis B surface antigen （HBsAg）-positive and HBsAg-negative/hepatitis B core antibody-positive patients was 13% （3/24） and 4% （3/69）, respectively. Conclusions： R-chemo is effective and safe in real-world clinical practice as first-line treatment for DLBCL and FL in China, and that HBV reactivation during R-chemo is manageable with preventive measur

关键词： Asian Hematopoietic Malignancy Hepatitis B Virus Observational Study Rituximab

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Consensus on the digestive endoscopic tunnel technique

引用

World Journal of Gastroenterology 2019年第7期25卷 744-776页

作者： Ning-Li Chai Hui-Kai Li En-Qiang Linghu Zhao-Shen Li Shu-Tian Zhang Yu Bao Wei-Gang Chen Philip WY Chiu Tong Dang Wei Gong Shu-Tang Han Jian-Yu Hao Shui-Xiang He Bing Hu1 Bing Hu2 Xiao-Jun Huang Yong-Hui Huang Zhen-Dong Jin Mouen A Khashab James Lau Peng Li Rui Li De-Liang Liu Hai-Feng Liu Jun Liu Xiao-Gang Liu Zhi-Guo Liu Ying-Cai Ma Gui-Yong Peng Long Rong Wei-Hong Sha Pateek Sharma Jian-Qiu Sheng Shui-Sheng Shi Dong Wan Seo Si-Yu Sun Gui-Qi Wang Wen Wang Qi Wu Hong Xu Mei-Dong Xu Ai-Ming Yang Fang Yao Hong-Gang Yu Ping-Hong Zhou Bin Zhang Xiao-Feng Zhang Ya-Qi Zhai Department of Gastroenterology and Hepatology Chinese PLA General HospitalBeijing 100853China Department of Gastroenterology Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Gastroenterology the First Affiliated Hospital of Xi’an Jiao Tong UniversityXi’an 710000Shaanxi ProvinceChina Department of Gastroenterology West China HospitalSichuan UniversityChengdu 610041Sichuan ProvinceChina Department of Endoscopy Eastern Hepatobiliary Surgical Hospital Affiliated to Naval Medical UniversityShanghai 200438China Department of Gastroenterology the Second Hospital of Lanzhou UniversityLanzhou 730030Gansu ProvinceChina Department of Gastroenterology Peking University Third HospitalBeijing 100191China Division of Gastroenterology and Hepatology the Johns Hopkins University School of MedicineBaltimoreMD 21218United States Department of Gastrointestinal Endoscopy Prince of Wales Hospitalthe Chinese University of Hong KongHong KongChina Department of Gastroenterology the First Affiliated Hospital of Soochow UniversitySuzhou 215006Jiangsu ProvinceChina Department of Gastroenterology Second Xiangya Hospital of Central South UniversityChangsha 410000Hunan ProvinceChina Department of Gastroenterology Changhai HospitalNaval Medical UniversityShanghai 200433China Department of Gastroenterology General Hospital of Chinese People’s Armed Police ForcesBeijing 100039China Division of Gastroenterology Union Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022Hubei ProvinceChina Department of Gastroenterology Sichuan Provincial People’s HospitalChengdu 610072Sichuan ProvinceChina Department of Gastroenterology Xijing HospitalAir Force Medical UniversityXi’an 710032Shaanxi ProvinceChina Department of Digestion Qinghai Provincial People’s HospitalXining 810007Qinghai ProvinceChina Department of Gastroenterology Southwest HospitalArmy Medical UniversityChongqing 400038China Department of Gastroenterology Peking Univ

With the digestive endoscopic tunnel technique(DETT), many diseases that previously would have been treated by surgery are now endoscopically curable by establishing a submucosal tunnel between the mucosa and muscularis propria(MP). Through the tunnel, endoscopic diagnosis or treatment is performed for lesions in the mucosa, in the MP, and even outside the gastrointestinal(GI) *** present, the tunnel technique application range covers the following:(1)Treatment of lesions originating from the mucosal layer, e.g., endoscopic submucosal tunnel dissection for oesophageal large or circular early-stage cancer or precancerosis;(2) treatment of lesions from the MP layer, per-oral endoscopic myotomy, submucosal tunnelling endoscopic resection, etc.; and(3) diagnosis and treatment of lesions outside the GI tract, such as resection of lymph nodes and benign tumour excision in the mediastinum or abdominal cavity. With the increasing number of DETTs performed worldwide, endoscopic tunnel therapeutics, which is based on DETT, has been gradually developed and optimized. However, there is not yet an expert consensus on DETT to regulate its indications, contraindications, surgical procedure, and postoperative *** International DETT Alliance signed up this consensus to standardize the procedures of DETT. In this consensus, we describe the definition, mechanism,and significance of DETT, prevention of infection and concepts of DETTassociated complications, methods to establish a submucosal tunnel, and application of DETT for lesions in the mucosa, in the MP and outside the GI tract(indications and contraindications, procedures, pre-and postoperative treatments, effectiveness, complications and treatments, and a comparison between DETT and other operations).

关键词： Digestive endoscopic tunnel technique Endoscopic submucosal tunnel dissection Per-oral endoscopic myotomy Submucosal tunnelling endoscopic resection Gastrointestinal tract

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

评价西格列他钠在2型糖尿病患者中疗效与安全性的随机、双盲、安慰剂对照的Ⅲ期临床试验(CMAP)

引用

Science Bulletin 2021年第15期66卷 1571-1580,M0004页

作者：纪立农宋卫红房辉李伟耿建林王颜刚郭莲蔡寒青杨涛李洪梅杨刚毅李启富刘宽芝李淑英刘彦君石福彦李新胜高鑫田浩明姬秋和苏青周智广王闻博周尊海李学军徐焱成宁志强曹海湘潘德思姚何鲁先平贾伟平 Peking University People’s Hospital Beijing 100044China Chenzhou No.1 People’s Hospital Chenzhou 423000China Tangshan Gongren Hospital Tangshan 063000China The Affiliated Hospital of Xuzhou Medical College Xuzhou 221006China Harrison International Peace Hospital Hengshui 053000China The Affiliate Hospital of Qingdao University Qingdao 266003China Chongqing Three Gorges Central Hospital Chongqing 404000China The Second Hospital of Jilin University Changchun 130041China Jiangsu Province Hospital Nanjing 210029China China Meitan General Hospital Beijing 100028China The Second Affiliate Hospital of Chongqing Medical University Chongqing 400010China The First Affiliate Hospital of Chongqing Medical University Chongqing 400016China The Third Hospital of Hebei Medical University Shijiazhuang 050051China Tianjin Medical University General Hospital Tianjin 300052China The 306th Hospital of PLA Beijing 100101China Baogang Hospital of Inner Mongolia Baotou 014010China Cangzhou’s Central Hospital Cangzhou 031706China Zhongshan Hospital Fudan University Shanghai 200032China Huaxi Hopsital of Sichuan University Chengdu 610041China The First Affiliated Hospital of The 4th Military Medical University Xi’an 710000China Xin Hua Hospital Affiliated to Shanghai Jiaotong University school of medicine Shanghai 200092China The Second xiangya Hospital of Central South University Changsha 410008China Peking University Shougang Hospital Beijing 100144China The Central Hospital of Yangpu District of Shanghai Shanghai 200090China The First Affiliate Hospital of Xiamen University Xiamen 361003China Zhongnan Hospital of Wuhan University Wuhan 430071China Shenzhen Chipscreen Biosciences Co. Ltd.Shenzhen 518057China Shanghai 6th People’s Hospital Shanghai 200233China

西格列他钠(Chiglitazar,CGZ)是一种新型非噻唑烷二酮类结构的过氧化物酶体增殖物激活受体(PPAR)全激动剂,在Ⅱ期临床试验中显示出调控2型糖尿病(T2DM)患者的血糖和血脂作用.本项Ⅲ期临床试验比较CGZ与安慰剂(PBO)在经生活方式控制血糖... 详细信息

西格列他钠(Chiglitazar,CGZ)是一种新型非噻唑烷二酮类结构的过氧化物酶体增殖物激活受体(PPAR)全激动剂,在Ⅱ期临床试验中显示出调控2型糖尿病(T2DM)患者的血糖和血脂作用.本项Ⅲ期临床试验比较CGZ与安慰剂(PBO)在经生活方式控制血糖不佳的T2DM患者中的疗效和安全性.受试患者随机至CGZ 32 mg(n=167)、CGZ48 mg(n=166)或PBO(n=202)组,接受每日一次口服药物治疗.试验主要疗效终点指标为24周糖化血红蛋白(HbA_(1c))较基线的变化值.结果显示,CGZ 32 mg组和CGZ 48 mg组24周时的HbA_(1c)显著降低,其较PBO组的差异分别为-0.87%(95%CI:-1.10 to-0.65;P<0.0001)和-1.05%(95%CI:-1.29 to-0.81;P<0.0001),CGZ两个剂量组在其他血糖、血脂、胰岛素敏感性等次要疗效终点指标上也较PBO组呈现显著改善.各组间不良事件(AE)总发生率和因AE退出试验率相似,CGZ两组的轻度水肿和体重增加略高于PBO组.试验结果表明,西格列他钠对生活方式控制血糖不佳的T2DM患者具有总体良好的疗效和安全性,为这一PPAR全激动剂治疗T2DM提供了确证性临床试验证据.

关键词： Ⅲ期临床试验安慰剂对照疗效和安全性 Ⅱ期临床试验控制血糖疗效与安全性终点指标口服药物治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Guidelines for the diagnosis and treatment of acute pancreatitis in China (2021)

引用

Journal of Pancreatology 2021年第2期4卷 67-75页

作者： Fei Li Shouwang Cai Feng Cao Rufu Chen Deliang Fu Chunlin Ge Chunyi Hao Jihui Hao Heguang Huang Zhixiang Jian Gang Jin Ang Li Haimin Li Shengping Li Weiqin Li Yixiong Li Tingbo Liang Xubao Liu Wenhui Lou Yi Miao Yiping Mou Chenghong Peng Renyi Qin Chenghao Shao Bei Sun Guang Tan Xiaodong Tian Huaizhi Wang Lei Wang Wei Wang Weilin Wang Junmin Wei Heshui Wu Wenming Wu Zheng Wu Changqing Yan Yinmo Yang Xiaoyu Yin Xianjun Yu Chunhui Yuan Taiping Zhang Yupei Zhao on behalf of the Chinese Pancreatic Surgery Association Department of General Surgery Xuanwu HospitalCapital Medical UniversityBeijing Department of Hepatobiliary and Pancreatic Surgery the First Medical CenterChinese PLA General HospitalBeijing Pancreatic Center Guangdong Provincial People’s HospitalGuangzhouGuangdong Province Department of Pancreatic Surgery Huashan HospitalFudan UniversityShanghai Department of Pancreatic and Biliary Surgery The First Affiliated Hospital of China Medical UniversityShenyangLiaoning Province Department of Hepatopancreatobiliary Surgery Peking University Cancer HospitalBeijing Department of Pancreatic Cancer Tianjin Medical University Cancer Institute and HospitalTianjin Department of General Surgery Fujian Medical University Union HospitalFuzhouFujian Province Department of General Surgery Guangdong Provincial People’s HospitalGuangzhouGuangdong Province Department of Hepatobiliary Pancreatic Surgery Changhai Hospital Affiliated to Navy Medical UniversityShanghai Department of Hepatobiliary Surgery Xijing HospitalFourth Military Medical UniversityXi’anShaanxi Province Department of Pancreatobiliary Surgery Sun Yat-sen University Cancer CenterGuangzhouGuangdong Province Department of General Surgery Jinling HospitalMedical School of Nanjing UniversityNanjingJiangsu Province Department of General Surgery Xiangya HospitalCentral South UniversityChangshaHunan Province Department of Hepatobiliary and Pancreatic Surgery the First Affiliated Hospital of Medical CollegeZhejiang UniversityHangzhouZhejiang Province Department of Pancreatic Surgery West China HospitalSichuan UniversityChengduSichuan Province Department of General Surgery Zhongshan HospitalFudan UniversityShanghai Pancreas Center The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu Province Department of Gastrointestinal and Pancreatic Surgery Zhejiang Provincial People’s HospitalHangzhouZhejiang Province Department of General Surgery Pancreatic Disease CenterRuijin HospitalShanghai Jiao Tong University School of Med

Acute pancreatitis(AP)is a common acute abdominal condition of the digestive *** recent years,treatment concepts,methods,and strategies for the diagnosis of AP have advanced,and this has played an important role in promoting the standardization of AP diagnosis and treatment and improving the treatment quality of AP *** the basis of previous guidelines and expert consensus,this guideline adopts an evidence-based,problem-based expression;synthesizes important clinical research data at home and abroad in the most recent 5 years;and forms 29 recommendations through multidisciplinary expert discussion,including diagnosis,treatment,and *** is expected to provide evidence support for the treatment of AP in the clinical setting in China.

关键词： Acute pancreatitis Diagnosis Follow-up Guideline Treatment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)

引用

Journal of Pancreatology 2021年第2期4卷 49-66页

作者： Yinmo Yang Xueli Bai Dapeng Bian Shouwang Cai Rufu Chen Feng Cao Menghua Dai Chihua Fang Deliang Fu Chunlin Ge Xiaochao Guo Chunyi Hao Jihui Hao Heguang Huang Zhixiang Jian Gang Jin Fei Li Haimin Li Shengping Li Weiqin Li Yixiong Li Hongzhen Li Tingbo Liang Xubao Liu Wenhui Lou Yi Miao Yiping Mou Chenghong Peng Renyi Qin Chenghao Shao Bei Sun Guang Tan Xiaodong Tian Huaizhi Wang Lei Wang Wei Wang Weilin Wang Junmin Wei Heshui Wu Wenming Wu Zheng Wu Jingyong Xu Changqing Yan Xiaoyu Yin Xianjun Yu Chunhui Yuan Taiping Zhang Jixin Zhang Jun Zhou Yupei Zhao on behalf of the Chinese Pancreatic Surgery Association Department of General Surgery Peking University First HospitalBeijing Department of Hepatobiliary and Pancreatic Surgery the First Affiliated Hospital of Medical CollegeZhejiang UniversityHangzhouZhejiang Province Departments of Endoscopy Peking University First HospitalBeijing Institute of Hepatobiliary Surgery of PLA Chinese PLA General HospitalBeijing Department of Pancreatobiliary Surgery Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong Province Department of General Surgery Xuanwu HospitalCapital Medical UniversityBeijing Department of General Surgery Peking Union Medical College HospitalChinese Academy of Medical Science&Peking Union Medical CollegeBeijing Department of Hepatobiliary Surgery Zhujiang HospitalSouthern Medical UniversityGuangzhouGuangdong Province Department of Pancreatic Surgery Huashan Hospital Fudan UniversityShanghai Department of General Surgery The First Affiliated Hospital of China Medical UniversityShenyangLiaoning Province Department of Imaging Peking University First HospitalBeijing Department of Hepato-Pancreato-Biliary Surgery Peking University Cancer Hospital&InstituteBeijing Department of Pancreatic Cancer Tianjin Medical University Cancer Institute and HospitalTianjin Department of General Surgery Fujian Medical University Union HospitalFuzhouFujian Province Department of General Surgery Guangdong Provincial People’s HospitalGuangzhouGuangdong Province Department of Hepatobiliary Pancreatic Surgery Changhai Hospital Affiliated to Navy Medical UniversityShanghai Department of Hepatobiliary Surgery Xijing HospitalFourth Military Medical UniversityXi’anShaanxi Province Department of Pancreatobiliary Surgery Sun Yat-sen University Cancer CenterGuangzhouGuangdong Province Department of General Surgery Jinling HospitalMedical School of Nanjing UniversityNanjingJiangsu Province Department of General Surgery Xiangya HospitalCentral South UniversityChangshaHunan Province Department of Radiation Oncology Peking University First H

The incidence of pancreatic cancer has been rising worldwide,and its clinical diagnosis and treatment remain a great *** present the update and improvements in the clinical diagnosis and treatment of pancreatic cancer in recent years,Chinese Pancreatic Association,the Chinese Society of Surgery,Chinese Medical Association revised the Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China(2014)after reviewing evidence-based and problem-oriented literature published during 2015-2021,mainly focusing on highlight issues regarding diagnosis and surgical treatment of pancreatic cancer,conversion strategies for locally advanced pancreatic cancer,treatment of pancreatic cancer with oligo metastasis,adjuvant and neoadjuvant therapy,standardized processing of surgical specimens and evaluation of surgical margin status,systemic treatment for unresectable pancreatic cancer,genetic testing,as well as postoperative follow up of patients with pancreatic *** recommendation items were finally proposed based on the above issues,and the quality of evidence and strength of recommendations were graded using the Grades of Recommendation,Assessment,Development,and Evaluation *** guideline aims to standardize the clinical diagnosis and therapy,especially surgical treatment of pancreatic cancer in China,and further improve the prognosis of patients with pancreatic cancer.

关键词： Diagnosis Guideline Multidisciplinary team Pancreatic cancer Treatment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B

引用

Journal of Clinical and Translational Hepatology 2019年第4期7卷 322-328页

作者： Shan Shan Hong You Junqi Niu Jia Shang Wen Xie Yuexin Zhang Xun Li Hong Ren Hong Tang Huiguo Ding Xihong Wang Yuemin Nan Xiaoguang Dou Tao Han Lingyi Zhang Xiaoqing Liu Cunliang Deng Jilin Cheng Xiaozhong Wang Qing Xie Shumei Lin Yan Huang Youqing Xu Yong Xiong Wu Li Xuebing Yan Hongxin Piao Wenxiang Huang Qinghua Lu Weijin Gong Shiping Li Xiaoxuan Hu Xiaolan Zhang Shourong Liu Yufang Li Dongliang Yang Hai Li Caixia Yang Mingliang Cheng Liaoyun Zhang Huanwei Zheng Xinhua Luo Feng Lin Lei Wang Guanghua Xu Xiaoyuan Xu Lai Wei Jinlin Hou Zhongping Duan Hui Zhuang Xizhong Yang Yuanyuan Kong Jidong Jia the CR-HepB study group,Beijing,China Liver Research Center Beijing Friendship HospitalCapital Medical UniversityBeijing Key Laboratory of Translational Medicine on Liver CirrhosisNational Clinical Research Center for Digestive DiseasesBeijingChina Department of Hepatology First Hospital of Jilin UniversityChangchunJilinChina Department of Infectious Diseases Henan Provincial People's HospitalZhengzhouHenanChina Center of Liver Diseases Beijing Ditan HospitalCapital Medical UniversityBeijingChina Department of Infectious Diseases First Affiliated Hospital of Xinjiang Medical UniversityUrumqiXinjiangChina Department of General Surgery The First Hospital of Lanzhou UniversityLanzhouGansuChina Department of Infectious Diseases The Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina Center of Infectious Diseases West China Hospital of Sichuan UniversityChengduSichuanChina Department of Gastroenterology and Hepatology Beijing Youan HospitalCapital Medical UniversityBeijingChina Center of Infectious Diseases The Third People's Hospital of TaiyuanTaiyuanShanxiChina Department of Traditional and Western Medical Hepatology The Third Hospital of Hebei Medical UniversityShijiazhuangHebeiChina Department of Infectious Diseases Shengjing Hospital of China Medical UniversityShenyangLiaoningChina Department of Hepatology Tianjin Third Central HospitalTianjin Medical UniversityTianjinChina Department of Hepatology Lanzhou University Second HospitalLanzhouGansuChina Department of Infectious Diseases Peking Union Medical College HospitalBeijingChina Department of Infectious Diseases The Affiliated Hospital of Southwest Medical UniversityLuzhouGansuChina Department of Gastroenterology Shanghai Public Health Clinical CenterShanghaiChina Department of Hepatology Xinjiang Uygur Autonomous Region Traditional Chinese Medicine HospitalUrumqiXinjiangChina Department of Infectious Diseases Shanghai Ruijin HospitalJiao Tong University School of MedicineShanghaiChina Department of Infectious Diseases Th

Background and Aims: Chronic hepatitis B virus(HBV)in-fection remains a major public health problem ***,we describe the baseline characteristics and treatment pro-files of HBV-infected patients recruited to the China Registry of Hepatitis ***: Inclusion criteria were patients with different stages of chronic HBV infection and complete key *** criteria were patients with hepatocellular *** baseline clinical,laboratory and treatment pro-files were ***: Finally,40,431 patients were *** median age was 43 years,with 65.2%being men and 51.3%being positive for hepatitis B e antigen(HBeAg).The most common initial diagnosis was chronic hep-atitis B(81.0%),followed by cirrhosis(9.3%),inactive carrier of hepatitis B surface antigen(HBsAg)(6.7%),and immune tolerant phase of hepatitis B infection(3.0%).Among the 21,228 patients who were on treatment,88.0%,10.0%and 2.0%received nucleos(t)ide analogues(NAs),interferon or combination of NAs and interferon,*** propor-tion of patients who received preferred NAs(entecavir or te-nofovir disoproxil fumarate)had increased from 13.5%in 2003 to 79.7%in ***: We concluded that middle-aged men accounted for most of the patients with chronic hepatitis B in this cross-sectional *** half of the patients were *** were the most com-monly used therapy,and use of the preferred NAs had steadily increased in the past decade.

关键词： Hepatitis B Treatment Registry

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database

引用

Asian Journal of Urology 2015年第2期2卷 63-69页

作者： Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang Department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouChina Chinese Bladder Cancer Consortium Department of Urology Renji HospitalShanghai Jiaotong University School of MedicineShanghaiChina Department of Urology Fujian Medical University Union HospitalFuzhouChina Department of Urology General Hospital of Ningxia Medical UniversityYinchuanChina Department of Urology Peking University Third HospitalBeijingChina Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefeiChina Department of Urology The Xinjiang Uygur Autonomous Region People’s HospitalUygurChina Department of Urology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina Department of Urology The First Affiliated Hospital of Guangxi Medical UniversityNanningChina Department of Urology Southwest HospitalThird Military Medical UniversityChongqingChina Department of Urology Daping HospitalThird Military Medical UniversityChongqingChina Department of Urology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Department of Urology The First Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Urology Peking University First HospitalBeijingChina Department of Urology The First Affiliated Hospital of Zhejiang UniversityHangzhouChina Department of Urology China Japan Friendship Hospital of Jilin UniversityChangchunChina Department of Urology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Urology Wuhan General Hospital of Guangzhou MilitaryWuhanChina Department of Urology The First Affiliated Hospital of Shanxi UniversityTaiyuanChina Department of Urology Qilu Hospital of Shandong UniversityJinanChina Department of Urology West China HospitalSichuan UniversityChengduChina Department of Urology The Second Affiliated Hospital of Tianjin Medical UniversityTianjinChina Department of Urology Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Objective:To investigate current status of diagnosis and treatment of bladder cancer in ***:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were *** of diagnosis,treatment and pathology were ***:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,***-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,*** transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,*** MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,*** most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant ***:Disease characteristics are similar to international reports,while differences of diagnosis and treatment *** study can provide evidences for revisions of the guideline on bladder cancer in China.

关键词： Bladder cancer Diagnosis Treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Expert consensus on the perioperative management of patients with sepsis

引用

World Journal of Emergency medicine 2015年第4期6卷 245-260页

作者： Jun-ping Chen Xiang-ming Fang Xiao-ju Jin Rong-tian Kang Ke-xuan Liu Jin-bao Li Yan Luo Zhi-jie Lu Chang-hong Miao Han-xiang Ma Wei Mei Yang-wen Ou Si-hua Qi Zai-sheng Qin Guo-gang Tian An-shi Wu Dong-xin Wang Tian Yu Yong-hao Yu Jing Zhao Ming-zhang Zuo Shi-hai Zhang Department of Anesthesiology Ningbo Number 2 Hospital Department of Anesthesiology First Affiliated HospitalSchool of MedicineZhejiang University Department of Anesthesiology and Critical Care medicine Yijishan HospitalWannan Medical College Department of Anesthesiology Second Hospital of Hebei Medical University Department of Anesthesiology First Affiliated HospitalSun Yat-sen University Department of Anesthesiology and Intensive Care medicine Changhai HospitalSecond Military Medical University Department of Anesthesiology Ruijin HospitalSchool of MedicineShanghai Jiaotong University Department of Anesthesiology and Intensive Care medicine Eastern Hepatobiliary Surgery HospitalSecond Military Medical University Department of Anesthesiology Fudan University Shanghai Cancer CenterShanghai Medical CollegeFudan University Department of Anesthesiology General Hospital of Ningxia Medical University Department of Anesthesiology Tongji HospitalTongji Medical CollegeHuazhong University of Science and Technology Department of Anesthesiology Third Xiangya HospitalCentral South University Department of Anesthesiology Fourth Affiliated HospitalHarbin Medical University Department of Anesthesiology Nanfang HospitalSouthern Medical University Department of Anesthesiology People's Hospital of Sanya Department of Anesthesiology Beijing Chaoyang HospitalCapital Medical University Department of Anesthesiology and Surgical Intensive Care Peking University First Hospital Department of Anesthesiology Affiliated Hospital of Zunyi Medical College Department of Anesthesiology Tianjin Medical University General Hospitaland Tianjin Research Institute of Anesthesiology Department of Anesthesiology Peking Union Medical College HospitalChinese Academy of Medical Sciences Department of Anesthesiology Beijing Hospital Department of Anesthesiology Union HospitalTongji Medical CollegeHuazhong University of Science and Technology

INTRODUCTION Sepsis is defined as an infection associated with systemic manifestations of inflammation,which has become the most common complication in the perioperative period caused by severe burn/trauma and major surgical operation.^([1,2])The incidence of sepsis in adults is estimated to be 149–240/100 000 per year,and that of severe sepsis and septic shock is 56–91/100 000per *** the last decade,the short-term

关键词： Expert consensus on the perioperative management of patients with sepsis ARDS Hg

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Guidelines for Diagnosis and Treatment of Atopic Dermatitis in China(2020)#

引用

International Journal of Dermatology and Venereology 2021年第1期4卷 1-9页

作者： Xu Yao Zhi-Qiang Song Wei Li Yun-Sheng Liang Yan Zhao Hua Cao Tao Chen Xue Chen Ai-Ping Feng Song-Mei Geng Heng Gu Shu-Ping Guo Yan-Ling He Ye-Hong Kuang Chun-Ying Li Xiao-Hong Li Zheng-Xiao Li Jun-Qin Liang Hong-Ye Liu Ling-Ling Liu Yu-Mei Liu Zhi Liu Hai Long Qian-Jin Lu Yan Lu Xiao-Qun Luo Xiao-Yan Lv Lin Ma Zhu Shen Xin Shi Zhong-Xiang Shi Xiang-Yang Su Qing Sun Jian-Ping Tang Ao-Xue Wang Hui-Ping Wang Jian-Qin Wang Ming-Yue Wang Zai-Xing Wang Yu-Min Xia Ting Xiao Zhi-Qiang Xie Huan Xing Ying Xiong Zi-Gang Xu Bin Yang Zhi-Rong Yao Jian-Bin Yu Nan Yu Kang Zeng Jian-Zhong Zhang Jun-Ling Zhang Hua Zhao Zuo-Tao Zhao Wei Zhu Ying-Hua Zhu Ying Zou Atopic Dermatitis Working Group,Immunology Group,Chinese Society of Dermatology Hospital for Skin Diseases(Institute of Dermatology) Chinese Academy of Medical SciencesNanjingJiangsu 210042China Southwest Hospital of Military Medical University Chongqing 400038China Huashan Hospital Affiliated with Fudan UniversityShanghai 200040China Dermatology Hospital of Southern Medical University GuangzhouGuangdong 510091China Peking University People’s Hospital Beijing 100044China Ruijin Hospital Affiliated with Shanghai Jiaotong UniversityShanghai 310000China Chengdu Second People’s Hospital ChengduSichuan 610017China Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology WuhanHubei 430022China The Second Affiliated Hospital of Xi’an Jiaotong University Xi’anShaanxi 710004China First Hospital of Shanxi Medical University TaiyuanShanxi 030012China Beijing Chao-Yang Hospital Capital Medical UniversityBeijing 100027China xiangya Hospital Central South UniversityChangshaHunan 410008China Xijing Hospital Fourth Military Medical UniversityXi’anShaanxi 710032China The First Affiliated Hospital of Zhengzhou University ZhengzhouHenan 450052China People’s Hospital of Xinjiang Uygur Autonomous Region WulumuqiXinjiang 830001China Peking University First Hospital Beijing 100034China Guangzhou Institute of Dermatology GuangzhouGuangdong 510095China The Affiliated Hospital of Guizhou Medical University GuiyangGuizhou 550004China The Second xiangya Hospital of Central South University ChangshaHunan 410011China The First Affiliated Hospital of Nanjing Medical University NanjingJiangsu 210029China West China Hospital Sichuan UniversityChengduSichuan 610041China Beijing Children’s Hospital Capital Medical UniversityBeijing 100045China Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital ChengduSichuan 610072China The Second Affiliated Hospital of Soochow University SuzhouJiangsu 215004China Shandong Provincial Dermatology Hospital JinanShandong 250022China The Third Affiliated Hospital of Sun Yat-sen U

Atopic dermatitis(AD)is a common disease clinically characterized by chronic recurrent eczematous lesions,dry skin,and *** can negatively impact patients’quality of *** prevalence of AD in China has been increasing during the past few *** on the most recent advances in the treatment of AD,we updated the 2014 version of the Guidelines for Diagnosis and Treatment of Atopic Dermatitis in China regarding the definition,epidemiology,pathogenesis,clinical classification,diagnosis,prevention,and treatment of AD.

关键词： atopic dermatitis diagnosis therapy guideline

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population

引用

Asian Journal of Urology 2019年第1期6卷 114-121页

作者： Liqun Zhou Kaiwei Yang Xuesong Li Yi Ding Dawei Mu Hanzhong Li Yong Yan Jinyi Li Dongwen Wang Wei Li Yulong Cong Jiangping Gao Kewei Ma Yajun Xiao Sheng Zhang Hongyi Jiang Weilie Hu Qiang Wei Xunbo Jin Zhichen Guan Qingyong Liu Danfeng Xu Xin Gao Yongguang Jiang Weimin Gan Guang Sun Qing Wang Yanhui Liu Jianquan Hou Liping Xie Xishuang Song Fengshuo Jin Jiafu Feng Ming Cai Zhaozhao Liang Jie Zhang Dingwei Ye Lin Qi Lulin Ma Jianzhong Shou Yuping Dai Jianyong Shao Ye Tian Shizhe Hong Tao Xu Chuize Kong Zefeng Kang Yuexin Liu Xun Qu Benkang Shi Shaobin Zheng Yi Lin Shujie Xia Dong Wei Jianbo Wu Weiling Fu Zhiping Wang Jianbo Liang Department of Urology Peking University First HospitalBeijingChina Institute of Urology Peking UniversityBeijingChina National Urological Cancer Center BeijingChina Air Force General Hospital PLABeijingChina Department of Urology Peking Union Medical College HospitalBeijingChina Department of Urology Beijing Chao-Yang HospitalBeijingChina Department of Urology Armed-Police General HospitalBeijingChina Department of Urology Shanxi Medical University First HospitalTaiyuanChina Department of Urology Hebei Medical University Second HospitalShijiazhuangChina Department of Urology The General Hospital of the People’s Liberation ArmyBeijingChina Department of Urology First Affiliated Hospital of Jilin UniversityChangchunChina Department of Urology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina Department of Pathology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina Department of Urology The Second Xiangya Hospital of Central South UniversityChangshaChina Department of Urology General Hospital of Guangzhou Military Command of PLAGuangzhouChina Department of Urology West China School of MedicineChengduChina Department of Urology Shangdong Province-owned HospitalJinanChina Department of Urology Peking University Shenzhen HospitalShenzhenChina Department of Urology The Central Hospital of Jinan CityJinanChina Department of Urology Shanghai Changzheng HospitalShanghaiChina Department of Urology The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina Department of Urology Beijing Anzhen Hospital of Capital Medical UniversityBeijingChina Department of Urology The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina Department of Urology The Second Hospital of Tianjin Medical UniversityTianjinChina Department of Urology People’s Hospital of Xinjiang Uygur Autonomous RegionWulumuqiChina Department of Urology Guangdong General HospitalGuangzhouChina Department of Urology The First Affil

Objective:To evaluate the diagnostic value of fluorescence in situ hybridization(FISH)in bladder ***:We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December *** operating characteristic(ROC)curve analysis was performed and the area under curve(AUC)values were calculated for both the FISH and urine cytology ***:A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population.A total of 4807 patients with hematuria were prospectively,randomly enrolled for the simultaneous analysis of urine cytology,FISH testing,and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised ***,the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%,while that of cytology was 33.4%(p<0.001).The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7%and 89.6%,respectively(p=0.004).The sensitivity values of FISH for low and high grade bladder cancer were 82.6%and 90.1%,respectively(p=0.002).Conclusion:FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and *** sensitivity using FISH was obtained in high grade and muscle invasive tumors.

关键词： Bladder transitionalcell carcinoma Fluorescence in situ hybridization Detection Grade Stage

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：